In Vienna, at the gathering of Europe's retinal specialists, a small biotechnology company offered something rare to tens of thousands of people living in progressive darkness: early evidence that gene therapy may one day halt or reverse inherited blindness. AAVantgarde Bio presented clinical results suggesting that its dual-AAV approach — threading two viral messengers together to deliver genetic instructions too large for a single carrier — produced measurable visual improvements in patients with Usher syndrome, while preclinical data for a Stargardt disease therapy showed the biological mac
AAVantgarde Reports Early Visual Improvements in Gene Therapy Trial for Inherited Retinal Disease
Approximately 20,000 patients with Usher syndrome type 1B and 60,000-75,000 with Stargardt disease in the U.S. and EU currently have no approved treatments for progressive vision loss.
Seven of twelve patients showed visual improvement after six months
Mark
So these are gene therapies that use two viruses instead of one. Why does that matter?
Mimi
The genes these patients need are too big to fit in a single AAV vector. The MYO7A gene is 6.7 kilobases, ABCA4 is 6.8. A standard AAV can only carry about 4.7. So they engineered two smaller vectors that work together—each carries part of the genetic instructions, and inside the cell they reassemble into the full gene.
Luke
And that actually works? In humans?
Mimi
In the Usher trial, yes—no serious adverse events in 15 patients, and seven of twelve showed visual improvement after six months. But it's early. Twelve people with six months of follow-up is not a large dataset.
Mark
What kind of improvement are we talking about?
Mimi
Visual acuity improved by at least one line on the eye chart in seven patients. Four of those improved by two lines. In dim light, six improved by at least one line, four by three or more. That's meaningful for someone losing vision, but we don't know if it holds or gets better.
Luke
How do we know it's the therapy and not just natural variation or measurement error?
Mimi
That's a fair question. This is an open-label trial, so there's no control group. The company is relying on the pattern of improvement and the biological plausibility—the therapy is in the eye, the improvement is in vision.
Mark
And the Stargardt data?
Mimi
That's all preclinical—animal models. Pigs and primates showed the therapy produces the full protein and reduces toxic accumulation. But no human data yet.
Luke
So we're comparing a small human trial with early signals to animal data that looks promising. That's the actual state of play.
Mimi
Exactly. Both programs are moving forward, but both are still in early stages.
Mark
What happens next?
Mimi
LUCE-1 continues with longer follow-up. CELESTE, the Stargardt trial, is recruiting now. We'll see if the visual improvements in Usher patients persist and whether AAVB-039 shows similar safety and benefit in humans.
O Pulso
- Roughly 80,000 to 95,000 people across the U.S. and EU are losing their sight to Usher syndrome or Stargardt disease with no approved therapy available to slow the damage.
- The core scientific obstacle — that the genes responsible for both diseases are simply too large to fit inside a standard viral delivery vehicle — has long blocked progress, making AAVantgarde's dual-AAV workaround a critical test of concept.
- In 15 treated Usher patients, no serious adverse events emerged, and 7 of 12 with six months of follow-up gained at least one line of visual acuity — a signal modest enough to demand caution but strong enough to sustain momentum.
- Preclinical work for the Stargardt therapy showed the diseased retina accepting the corrective protein at levels exceeding natural production, with toxic byproduct accumulation visibly reduced in treated tissue.
- Both programs are now advancing toward or into human trials, with the field watching closely to see whether early biological promise survives contact with the full complexity of human disease.
In Vienna, at the gathering of Europe's retinal specialists, a small biotechnology company offered something rare to tens of thousands of people living in progressive darkness: early evidence that gene therapy may one day halt or reverse inherited blindness. AAVantgarde Bio presented clinical results suggesting that its dual-AAV approach — threading two viral messengers together to deliver genetic instructions too large for a single carrier — produced measurable visual improvements in patients with Usher syndrome, while preclinical data for a Stargardt disease therapy showed the biological machinery behaving as hoped. For conditions that have never had an approved treatment, even cautious optimism carries profound weight.
At the European Society of Retina Specialists conference in Vienna, AAVantgarde Bio presented early clinical results for AAVB-081, its gene therapy for Usher syndrome type 1B — a rare inherited condition that leaves children deaf from birth and gradually strips away their vision through the first decade of life. Around 20,000 people in the U.S. and EU live with the disease, and none have an approved treatment to turn to.
The challenge has always been biological: the MYO7A gene responsible for the disease is too large to fit inside a single viral vector, the standard delivery mechanism for gene therapies. AAVantgarde's answer is a dual-AAV system — two modified viruses working in concert to carry the full genetic payload into the eye. Their LUCE-1 trial enrolled 15 patients across three dose levels, completing enrollment in January 2026.
The interim data, analyzed in early August, offered a cautiously encouraging picture. No serious adverse events occurred, no patients withdrew, and eye inflammation — a known risk with this class of therapy — remained mild and manageable. Among the 12 patients in the lower dose cohorts with at least six months of follow-up, seven achieved a one-line improvement in standard visual acuity, with four of those gaining two lines or more. Vision in dim light showed similar patterns of improvement. The company was careful to frame these as early findings from a small group, with longer follow-up still needed.
The conference also brought the first public presentation of preclinical data for AAVB-039, AAVantgarde's therapy for Stargardt disease — the most common inherited form of macular degeneration, affecting 60,000 to 75,000 people in the U.S. and EU. Like Usher syndrome, Stargardt has no approved treatment, and its causative gene, ABCA4, poses the same size problem for delivery. Tested in mice, pigs, and non-human primates, the dual-AAV approach produced full-length corrective protein at levels exceeding natural production and meaningfully reduced the accumulation of lipofuscin, the toxic cellular debris that drives retinal damage. Side effects were mild and temporary.
AAVantgarde is now enrolling patients for CELESTE, a Phase 1/2 trial of AAVB-039 in the U.S., U.K., and Europe, supported by a completed 150-patient natural history study establishing how the disease progresses without intervention. The coming months will test whether the visual gains seen in Usher patients deepen with time — and whether the biological precision demonstrated in animal models can hold when the therapy finally meets human eyes.
At the European Society of Retina Specialists conference in Vienna this week, a biotechnology company called AAVantgarde presented results from an early-stage trial of a gene therapy designed to treat Usher syndrome type 1B, a rare inherited disease that causes progressive blindness. The company also unveiled preclinical data for a second therapy targeting Stargardt disease, the most common form of inherited macular degeneration. Both conditions currently have no approved treatments.
Usher syndrome type 1B affects roughly 20,000 people across the United States and European Union. Children born with the condition are deaf from birth and gradually lose their vision starting in the first decade of life. The disease is caused by mutations in the MYO7A gene, which produces a protein essential for retinal function. The gene itself is too large to fit into a standard viral vector, so AAVantgarde developed a dual-AAV approach—essentially two modified viruses working together to deliver the full genetic instructions into the eye.
The trial, called LUCE-1, enrolled 15 patients across three dose levels and completed enrollment in January 2026. As of early August, when the company analyzed the data, no serious adverse events or dose-limiting toxicities had been reported. No participants had dropped out. Inflammation in the eye, which can be a concern with gene therapies, remained mild and responsive to corticosteroid treatment. Among the 12 patients in the lower two dose cohorts who had been followed for at least six months, the results suggested early visual benefit. Seven achieved at least a one-line improvement in best-corrected visual acuity—the standard measure of how clearly someone can see—with four of those seven improving by two lines or more. Six participants showed at least a one-line improvement in low-luminance visual acuity, a measure of vision in dim light, with four improving by three lines or more. Additional exploratory measures of fixation stability and visual field sensitivity also showed supportive signals in several patients.
These are early findings from a small group, and the company emphasized that longer follow-up will be needed to understand the full trajectory of benefit. But the safety profile and the pattern of visual improvement in the first six months provide enough encouragement to continue the trial and move toward larger studies.
The second program, AAVB-039, targets Stargardt disease, which affects an estimated 60,000 to 75,000 people in the U.S. and EU. The disease stems from mutations in the ABCA4 gene, which normally helps clear toxic byproducts from photoreceptor cells. When the gene is defective, these byproducts accumulate, damaging the retina and causing progressive vision loss, typically beginning in childhood or early adulthood. Like the MYO7A gene, ABCA4 is too large for a single AAV vector.
AAVantgarde's preclinical work, presented by Prof. Paulo Eduardo Stanga, tested the dual-AAV approach in mice, pigs, and non-human primates. In a pig model of Stargardt disease, the therapy produced full-length ABCA4 protein at levels exceeding 100 percent of what the animals naturally produce, and reduced the accumulation of lipofuscin—the toxic byproduct—in treated retinal areas compared to untreated controls. In primates, between 76 and 99 percent of photoreceptors took up both viral components across roughly 60 percent of the analyzed retinal section. Side effects were mild and temporary, with changes in electrical activity of the retina that were dose-related and resolved over time, and minimal histological damage that improved with observation.
The company is now moving AAVB-039 into human testing through two studies: a natural history study that has finished enrolling 150 Stargardt patients to establish how the disease progresses untreated, and a Phase 1/2 trial called CELESTE that is currently recruiting patients in the United States, United Kingdom, and Europe. CEO Jayashree Sahni said the data across both programs support continued development of the dual-AAV platform for these two currently untreatable diseases. The next phase will be watching whether the early visual improvements in Usher patients hold and expand with longer follow-up, and whether the preclinical promise of AAVB-039 translates into clinical benefit when the therapy reaches human eyes.
Citações Notáveis
The data presented at EURetina 2026 provide important updates across both of our lead programs. The continued absence of serious adverse events or dose-limiting toxicities, together with early signals of improved visual function in the low- and mid-dose cohorts, support the continued development of AAVB-081 in Usher syndrome type 1B.— Dr. Jayashree Sahni, CEO of AAVantgarde
Quer a matéria completa?
Leia o original em markets.businessinsider.com ↗